This marks the fifth national registration of OZILIA under the Madrid Protocol, meaning that the trademark is now registered in the U.S., Israel, Japan, China, and the United Kingdom. A corresponding application for registration in Brazil is currently under review. Since 2023, the trademark has also been registered in the European Union.

“The OZILIA trademark has been well received by the market, and protecting it through registrations is part of our IP strategy aimed at building long-term value in the company and making the business more attractive to potential buyers,” says Anders Weilandt, CEO of Chordate Medical.

In the article, Margareta Hoas shares her story of a life marked by chronic migraines, numerous failed treatment attempts and medications, and how Ozilia has finally provided her with noticeable relief.

“It makes a big difference for me. It brings the pain down two notches on the scale and makes life more bearable,” she tells the newspaper.

Migraine expert Lars Edvinsson, Professor of Internal Medicine at Lund University, also sees potential in the method as a possible complement to established CGRP inhibitors – medications currently used to prevent migraine attacks but which don’t work for everyone.

“These [CGRP inhibitors] have helped a large portion of those suffering from migraines. But there is still a group of patients that does not respond to the treatment. If the results hold up, the [Ozilia] method could function as a complement to already established CGRP inhibitor treatments,” he tells Svenska Dagbladet.

Read the full article (In Swedish)